Santaris Pharma, miRagen collaborate to develop microRNA-targeted medicines for cardiovascular disease

March 10, 2017

The unique combination of pharmaceutical properties, small size and very high affinity of LNA-based drugs developed utilizing Santaris Pharma A/S LNA Drug Platform allows this new class of drugs to potently and specifically inhibit RNA-targets in many different tissues without the need for complex delivery vehicles.

"We are very enthusiastic about our collaboration with Santaris Pharma, which provides us with what we believe is best-in-class technology to advance our mission of developing innovative microRNA-based therapies intended for the treatment of patients with cardiovascular and muscle disease," said William S. Marshall, Ph.D., President and CEO of miRagen Therapeutics.  "Santaris Pharma's LNA drug platform, which has produced compounds already in the clinic, can help to accelerate our development programs by providing the most effective anti-microRNA chemistry we've explored to date."

SOURCE Santaris Pharma A/S; miRagen Therapeutics, Inc.